Maxim downgraded Theriva Biologics (TOVX) to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics prices 6.8M shares at $1.10 in public offering
- Theriva Biologics announces primary endpoints for efficacy met in VIRAGE study
- Theriva Biologics Announces Positive VIRAGE Phase 2b Results
- Theriva Biologics Reports Positive VIRAGE Phase 2b Results
- Theriva Biologics says IDMC considers VCN-01 to be well tolerated